CONMED Corporation (CNMD)

NYSE: CNMD · IEX Real-Time Price · USD
80.17
-1.82 (-2.22%)
Sep 30, 2022 4:00 PM EDT - Market closed
-2.22%
Market Cap 2.44B
Revenue (ttm) 1.04B
Net Income (ttm) -113.92M
Shares Out 30.47M
EPS (ttm) 2.10
PE Ratio 38.18
Forward PE 27.03
Dividend $0.80 (1.00%)
Ex-Dividend Date Sep 14, 2022
Volume 373,253
Open 82.15
Previous Close 81.99
Day's Range 80.02 - 83.67
52-Week Range 77.09 - 159.11
Beta 1.50
Analysts Buy
Price Target 123.93 (+54.6%)
Earnings Date Oct 25, 2022

About CNMD

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The comp... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jul 23, 1987
CEO Curt Hartman
Employees 3,800
Stock Exchange NYSE
Ticker Symbol CNMD
Full Company Profile

Financial Performance

In 2021, CONMED's revenue was $1.01 billion, an increase of 17.18% compared to the previous year's $862.46 million. Earnings were $62.54 million, an increase of 557.16%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CNMD stock is "Buy." The 12-month stock price forecast is 123.93, which is an increase of 54.58% from the latest price.

Price Target
$123.93
(54.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

3 days ago - Zacks Investment Research

CONMED Corporation to Participate in a Fireside Chat at the Morgan Stanley Global Healthcare Conference

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice Preside...

3 weeks ago - Business Wire

PDCO vs. CNMD: Which Stock Is the Better Value Option?

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Other symbols: PDCO
1 month ago - Zacks Investment Research

CONMED Corporation Announces Quarterly Cash Dividend

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2022 to all sha...

1 month ago - Business Wire

CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez

CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.

1 month ago - Zacks Investment Research

CONMED Completes Acquisition of Biorez, Inc.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held Biorez, Inc. Biorez is a medical device start-u...

1 month ago - Business Wire

PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Other symbols: PDCO
1 month ago - Zacks Investment Research

CONMED Announces Definitive Agreement to Acquire Biorez, Inc.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced a definitive agreement to acquire privately held Biorez, Inc. (Biorez), on a cash-free, debt-free basis, for cash considerat...

2 months ago - Business Wire

CONMED (CNMD) Down on In-Line Q2 Earnings & Lower 2022 View

CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth.

2 months ago - Zacks Investment Research

Conmed (CNMD) Q2 Earnings Meet Estimates

Conmed (CNMD) delivered earnings and revenue surprises of 0% and 1.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CONMED Corporation Announces Second Quarter 2022 Financial Results

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights Sales of $277.2 million increas...

2 months ago - Business Wire

PDCO or CNMD: Which Is the Better Value Stock Right Now?

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Other symbols: PDCO
2 months ago - Zacks Investment Research

Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

CONMED (CNMD) continues to gain momentum from a solid product portfolio and a strong General Surgery business. However, data security issues linger.

2 months ago - Zacks Investment Research

CONMED Corporation to Announce Second Quarter 2022 Financial Results on July 27, 2022

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2022 after the market close on Wednesday, July 27, 2022. The Co...

2 months ago - Business Wire

New Strong Sell Stocks for June 30th

WMT, EC, and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2022.

Other symbols: ECWMT
3 months ago - Zacks Investment Research

New Strong Sell Stocks for June 27th

CNMD, WMT, and CAH have been added to the Zacks Rank #5 (Strong Sell) List on June 27, 2022.

Other symbols: CAHWMT
3 months ago - Zacks Investment Research

CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout

CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.

3 months ago - Zacks Investment Research

CONMED Completes Acquisition of In2Bones Global, Inc.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held In2Bones Global Inc. Headquartered in Memphis, ...

3 months ago - Business Wire

New Strong Sell Stocks for June 7th

CNMD, CL, and CBAN have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2022.

Other symbols: CBANCL
3 months ago - Zacks Investment Research

CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Notes

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the pricing of $700 million aggregate principal amount of 2.25% convertible senior notes due 2027 in a private offering to q...

4 months ago - Business Wire

New Strong Sell Stocks for June 1st

CBAN, CNMD, and FNF have been added to the Zacks Rank #5 (Strong Sell) List on June 1, 2022.

Other symbols: CBANFNF
4 months ago - Zacks Investment Research

CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it intends to offer, subject to market conditions and other factors, $600 million aggregate principal amount of its con...

4 months ago - Business Wire

New Strong Sell Stocks for May 19th

ASX, CNMD, and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2022.

Other symbols: ASXBHC
4 months ago - Zacks Investment Research

New Strong Sell Stocks for May 17th

CNMD, CL, and T have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2022.

Other symbols: CLT
4 months ago - Zacks Investment Research